| scholarly article | Q13442814 |
| P50 | author | Sabine Zöchbauer-Müller | Q40484735 |
| Walter Klepetko | Q56055212 | ||
| P2093 | author name string | Clemens Aigner | |
| Adelheid End | |||
| Christoph Bichler | |||
| Daniela Kandioler | |||
| Erich Roth | |||
| Georgios Stamatis | |||
| Irene Kührer | |||
| Marcus Hudec | |||
| Martina Mittlböck | |||
| Michael Rolf Müller | |||
| Ronald Zwrtek | |||
| Sonja Kappel | |||
| Thomas Bachleitner | |||
| Victoria Tichy | |||
| Wilfried Eberhardt | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| lung cancer | Q47912 | ||
| P304 | page(s) | 1036-1041 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | The Journal of Thoracic and Cardiovascular Surgery | Q2795598 |
| P1476 | title | Growing clinical evidence for the interaction of the p53 genotype and response to induction chemotherapy in advanced non-small cell lung cancer | |
| P478 | volume | 135 |
| Q39834578 | Adenovirally mediated p53 overexpression diversely influence the cell cycle of HEp-2 and CAL 27 cell lines upon cisplatin and methotrexate treatment. |
| Q88818061 | An overview of mortality & predictors of small-cell and non-small cell lung cancer among Saudi patients |
| Q51121284 | Deep sequencing of the TP53 gene reveals a potential risk allele for non-small cell lung cancer and supports the negative prognostic value of TP53 variants. |
| Q49901846 | Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing |
| Q89634774 | Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe? |
| Q92716661 | Impact of KRAS and TP53 Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With STK11-Mutated Advanced Non-Small-Cell Lung Cancer |
| Q36801098 | Inauhzin Sensitizes p53-Dependent Cytotoxicity and Tumor Suppression of Chemotherapeutic Agents |
| Q38087850 | Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers |
| Q44327720 | P53 family proteins provide new insights into lung carcinogenesis and clinical treatment |
| Q36817080 | Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer |
| Q33411155 | Rplp1 bypasses replicative senescence and contributes to transformation. |
| Q36225859 | Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells |
| Q34559185 | TP53 Mutations in Nonsmall Cell Lung Cancer |
| Q41733541 | TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family |
| Q38858580 | The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer |
| Q90615401 | Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy |
| Q28396304 | Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer |
| Q26768521 | Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy |
Search more.